Welcome to the UPF Digital Repository

Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma



Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma

Blocked
Document Type: Article
Version: Accepted version
Date: 2018
Blocked

This item appears in the following Collection(s)

Search DSpace


Advanced Search

Browse

My Account

Statistics

Compliant to Partaking